Influence of antiplatelet pre-treatment on the risk of symptomatic intracranial haemorrhage after intravenous thrombolysis

Cerebrovascular Diseases

Volumn 26, Issue 2, 2008, Pages 126-133

  Bravo, Yolanda ^a   Martí Fàbregas, Joan ^b   Cocho, Dolores ^b   Rodriguez Yanez M ^f   Castellanos, M ^g   Perez De La Ossa N ^c   Roquer, J ^d   Obach, V ^e   Maestre, J ^h   Martí Vilalta, Josep Lluis ^b  

^a HOSPITAL UNIVERSITARIO DE BURGOS   (Spain)

^b HOSPITAL DE LA SANTA CREU I SANT PAU   (Spain)

^c Department of Neurology

^d HOSPITAL DEL MAR   (Spain)

^e HOSPITAL CLÍNIC   (Spain)

^f Instituto de Salud Carlos III   (Spain)

^g HOSPITAL JOSEP TRUETA   (Spain)

^h HOSPITAL UNIVERSITARIO VIRGEN DE LAS NIEVES   (Spain)

Author keywords

Acute stroke; Antiplatelet therapy; Symptomatic intracranial haemorrhage; Thrombolysis

Indexed keywords

ACETYLSALICYLIC ACID; ALTEPLASE; ANTITHROMBOCYTIC AGENT; CLOPIDOGREL; DIPYRIDAMOLE; FIBRINOLYTIC AGENT; TICLOPIDINE; TRIFUSAL; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; BRAIN HEMORRHAGE; BRAIN INFARCTION; CEREBROVASCULAR ACCIDENT; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; DETERIORATION; DRUG CONTRAINDICATION; DRUG INFUSION; FEMALE; FIBRINOLYTIC THERAPY; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MALE; NEUROIMAGING; NEUROLOGIC DISEASE; PREMEDICATION; PRIORITY JOURNAL; RISK ASSESSMENT; TREATMENT OUTCOME;

AGED; FEMALE; FIBRINOLYTIC AGENTS; HUMANS; INFUSIONS, INTRAVENOUS; INTRACRANIAL HEMORRHAGES; MALE; MIDDLE AGED; PATIENT SELECTION; PLATELET AGGREGATION INHIBITORS; RECOMBINANT PROTEINS; RETROSPECTIVE STUDIES; RISK ASSESSMENT; RISK FACTORS; SPAIN; STROKE; THROMBOLYTIC THERAPY; TISSUE PLASMINOGEN ACTIVATOR; TREATMENT OUTCOME;

EID: 49949107825     PISSN: 10159770     EISSN: None     Source Type: Journal    
DOI: 10.1159/000139659     Document Type: Article

References (46)

1. National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group: Tissue plasminogen activator for acute ischemic stroke. N Engl J Med 1995;333:1581-1587.
2. Wardlaw JM, Sandercock PA, Berge E: Thrombolytic therapy with recombinant tissue plasminogen activator for acute ischemic stroke: where do we go from here? A cumulative meta-analysis. Stroke 2003;34:1437-1442.
3. Fiorelli M, Bastianello S, von Kummer R, del Zoppo GJ, Larrue V, Lesaffre E, Ringleb AP, Lorenzano S, Manelfe C, Bozzao L: Hemorrhagic transformation within 36 h of a cerebral infarct: relationships with early clinical deterioration and 3-month outcome in the European Cooperative Acute Stroke Study I (ECASS I) cohort. Stroke 1999;30:2280-2284.
4. Trouillas P, von Kummer R: Classification and pathogenesis of cerebral hemorrhages after thrombolysis in ischemic stroke. Stroke 2006;37:556-561.
5. Larrue V, von Kummer R, del Zoppo G, Bluhmki E: Hemorrhagic transformation in acute ischemic stroke: potential contributing factors in the European Cooperative Acute Stroke Study. Stroke 1997;28:957-960.
6. Larrue V, von Kummer RR, Muller A, Bluhmki E: Risk factors for severe hemorrhagic transformation in ischemic stroke patients treated with recombinant tissue plasminogen activator: a secondary analysis of the European-Australasian Acute Stroke Study (ECASS II). Stroke 2001;32:438-441.
7. NINDS t-PA Stroke Study Group: Intracerebral hemorrhage after intravenous t-PA therapy for ischemic stroke. Stroke 1997;28:2109-2118.
8. Demchuk AM, Morgenstern LB, Krieger DW, Linda Chi T, Hu W, Wein TH, Hardy RJ, Grotta JC, Buchan AM: Serum glucose level and diabetes predict tissue plasminogen activator-related intracerebral hemorrhage in acute ischemic stroke. Stroke 1999;30:34-39.
9. Tanne D, Kasner SE, Demchuk AM, Koren-Morag N, Hanson S, Grond M, Levine SR: Markers of increased risk of intracerebral hemorrhage after intravenous recombinant tissue plasminogen activator therapy for acute ischemic stroke in clinical practice: the Multicenter rt-PA Stroke Survey. Circulation 2002;105:1679-1685.
10. Cocho D, Borrell M, Marti-Fabregas J, Montaner J, Castellanos M, Bravo Y, Molina-Porcel L, Belvis R, Diaz-Manera JA, Martinez-Domeno A, Martinez-Lage M, Millan M, Fontcuberta J, Marti-Vilalta JL: Pretreatment hemostatic markers of symptomatic intracerebral hemorrhage in patients treated with tissue plasminogen activator. Stroke 2006;37:996-999.
11. Marti-Fabregas J, Bravo Y, Cocho D, MartiVilalta JL, Diaz-Manera J, San Roman L, Puig M, Blanco M, Castellanos M, Millan M, Roquer J, Obach V, Maestre J: Frequency and predictors of symptomatic intracerebral hemorrhage in patients with ischemic stroke treated with recombinant tissue plasminogen activator outside clinical trials. Cerebrovasc Dis 2007;23:85-90.
12. Palumbo V, Boulanger JM, Hill MD, Inzitari D, Buchan AM: Leukoaraiosis and intracerebral hemorrhage after thrombolysis in acute stroke. Neurology 2007;68:1020-1024.
13. Multicentre Acute Stroke Trial-Italy (MASTI) Group: Randomised controlled trial of streptokinase, aspirin, and combination of both in treatment of acute ischaemic stroke. Lancet 1995;346:1509-1514.
14. Ciccone A, Motto C, Aritzu E, Piana A, Candelise L;MAST-I Collaborative Group, Multicentre Acute Stroke Trial-Italy: Risk of aspirin use plus thrombolysis after acute ischaemic stroke: a further MAST-I analysis. Lancet 1998;352:880.
15. Wilterdink JL, Bendixen B, Adams HP Jr, Woolson RF, Clarke WR, Hansen MD: Effect of prior aspirin use on stroke severity in the trial of Org 10172 in acute stroke treatment (TOAST). Stroke 2001;32:2836-2840.
16. CAST (Chinese Acute Stroke Trial) Collaborative Group: CAST: randomised placebo-controlled trial of early aspirin use in 20,000 patients with acute ischaemic stroke. Lancet 1997;349:1641-1649.
17. International Stroke Trial Collaborative Group: The International Stroke Trial (IST): a randomised trial of aspirin, subcutaneous heparin, both, or neither among 19435 patients with acute ischaemic stroke. Lancet 1997;349:1569-1581.
18. Schmulling S, Rudolf J, Strotmann-Tack T, Grond M, Schneweis S, Sobesky J, Thiel A, Heiss WD: Acetylsalicylic acid pretreatment, concomitant heparin therapy and the risk of early intracranial hemorrhage following systemic thrombolysis for acute ischemic stroke. Cerebrovasc Dis 2003;16:183-190.
19. Gorelick PB, Weisman SM: Risk of hemorrhagic stroke with aspirin use: an update. Stroke 2005;36:1801-1807.
20. Kumar S, Savitz S, Schlaug G, Caplan L, Selim M: Antiplatelets, ACE inhibitors, and statins combination reduces stroke severity and tissue at risk. Neurology 2006;66:1153-1158;discussion 35.
21. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ 2002;324:71-86.
22. Hart RG, Halperin JL, McBride R, Benavente O, Man-Son-Hing M, Kronmal RA: Aspirin for the primary prevention of stroke and other major vascular events: meta-analysis and hypotheses. Arch Neurol 2000;57:326-332.
23. He J, Whelton PK, Vu B, Klag MJ: Aspirin and risk of hemorrhagic stroke: a meta-analysis of randomized controlled trials. JAMA 1998;280:1930-1935.
24. Saloheimo P, Ahonen M, Juvela S, Pyhtinen J, Savolainen ER, Hillbom M: Regular aspirin use preceding the onset of primary intracerebral hemorrhage is an independent predictor for death. Stroke 2006;37:129-133.
25. Clark WM, Albers GW, Madden KP, Hamilton S;Thromblytic therapy in acute ischemic stroke study investigators: The rtPA (alteplase) 0- to 6-hour acute stroke trial, part A (A0276g): results of a double-blind, placebo-controlled, multicenter study. Stroke 2000;31:811-816.
26. Donnan GA, Davis SM, Chambers BR, Gates PC, Hankey GJ, McNeil JJ, Rosen D, Stewart-Wynne EG, Tuck RR: Streptokinase for acute ischemic stroke with relationship to time of administration: Australian Streptokinase (ASK) Trial Study Group. JAMA 1996;276:961-966.
27. Multicenter Acute Stroke Trial-Europe Study Group: Thrombolytic therapy with streptokinase in acute ischemic stroke. N Engl J Med 1996;335:145-150.
28. Jaillard A, Cornu C, Durieux A, Moulin T, Boutitie F, Lees KR, Hommel M;MAST-E Group: Hemorrhagic transformation in acute ischemic stroke: The MAST-E study. Stroke 1999;30:1326-1332.
29. Cornu C, Boutitie F, Candelise L, Boissel JP, Donnan GA, Hommel M, Jaillard A, Lees KR: Streptokinase in acute ischemic stroke: an individual patient data meta-analysis - The Thrombolysis in Acute Stroke Pooling Project. Stroke 2000;31:1555-1560.
30. Molina CA, Alvarez-Sabin J, Montaner J, Abilleira S, Arenillas JF, Coscojuela P, Romero F, Codina A: Thrombolysis-related hemorrhagic infarction: a marker of early reperfusion, reduced infarct size, and improved outcome in patients with proximal middle cerebral artery occlusion. Stroke 2002;33:1551-156.
31. Lindsberg PJ, Soinne L, Roine RO, Salonen O, Tatlisumak T, Kallela M, Happola O, Tiainen M, Haapaniemi E, Kuisma M, Kaste M: Community-based thrombolytic therapy of acute ischemic stroke in Helsinki. Stroke 2003;34:1443-1449.
32. Katzan IL, Furlan AJ, Lloyd LE, Frank JI, Harper DL, Hinchey JA, Hammel JP, Qu A, Sila CA: Use of tissue-type plasminogen activator for acute ischemic stroke: the Cleveland area experience. JAMA 2000;283:1151-1158.
33. Lansberg MG, Albers GW, Wijman CA: Symptomatic intracerebral hemorrhage following thrombolytic therapy for acute ischemic stroke: a review of the risk factors. Cerebrovasc Dis 2007;24:1-10.
34. Bednar MM, Quilley J, Russell SR, Fuller SP, Booth C, Howard D, Gross CE: The effect of oral antiplatelet agents on tissue plasminogen activator-mediated thrombolysis in a rabbit model of thromboembolic stroke. Neurosurgery 1996;39:352-359.
35. Levin RI, Harpel PC, Weil D, Chang TS, Rifkin DB: Aspirin inhibits vascular plasminogen activator activity in vivo: studies utilizing a new assay to quantify plasminogen activator activity. J Clin Invest 1984;74:571-580.
36. Topol EJ: Reperfusion therapy for acute myocardial infarction with fibrinolytic therapy or combination reduced fibrinolytic therapy and platelet glycoprotein IIb/IIIa inhibition: the GUSTO V randomised trial. Lancet 2001;357:1905-1914.
37. Ruiz-Bailen M, Brea-Salvago JF, de Hoyos EA, Rucabado-Aguilar L, Escudero GG, Martinez-Escobar S, Rossel-Ortiz F, Mellado-Vergel JF, Ruiz-Ferron F, Morante-Valle A, Gomez-Jimenez FJ, Colmenero-Ruiz M: Post-thrombolysis intracerebral hemorrhage: data from the Spanish Register ARIAM. Crit Care Med 2005;33:1829-1838.
38. Savonitto S, Armstrong PW, Lincoff AM, Jia G, Sila CA, Booth J, Terrosu P, Cavallini C, White HD, Ardissino D, Califf RM, Topol EJ: Risk of intracranial haemorrhage with combined fibrinolytic and glycoprotein IIb/IIIa inhibitor therapy in acute myocardial infarction: dichotomous response as a function of age in the GUSTO V trial. Eur Heart J 2003;24:1807-1814.
39. Meijer A, Verheugt FW, Werter CJ, Lie KI, van der Pol JM, van Eenige MJ: Aspirin versus coumadin in the prevention of reocclusion and recurrent ischemia after successful thrombolysis: a prospective placebo-controlled angiographic study - results of the APRICOT Study. Circulation 1993;87:1524-1530.
40. Sabatine MS, Cannon CP, Gibson CM, Lopez-Sendon JL, Montalescot G, Theroux P, Claeys MJ, Cools F, Hill KA, Skene AM, McCabe CH, Braunwald E: Addition of clopidogrel to aspirin and fibrinolytic therapy for myocardial infarction with ST-segment elevation. N Engl J Med 2005;352:1179-1189.
41. Alexandrov AV, Grotta JC: Arterial reocclusion in stroke patients treated with intravenous tissue plasminogen activator. Neurology 2002;59:862-867.
42. Rubiera M, Alvarez-Sabin J, Ribo M, Montaner J, Santamarina E, Arenillas JF, Huertas R, Delgado P, Purroy F, Molina CA: Predictors of early arterial reocclusion after tissue plasminogen activator-induced recanalization in acute ischemic stroke. Stroke 2005;36:1452-1456.
43. Clark WM, Madden KP, Lyden PD, Zivin JA: Cerebral hemorrhagic risk of aspirin or heparin therapy with thrombolytic treatment in rabbits. Stroke 1991;22:872-876.
44. Thomas GR, Thibodeaux H, Errett CJ, Bednar MM, Gross CE, Bennett WF: Intravenous aspirin causes a paradoxical attenuation of cerebrovascular thrombolysis. Stroke 1995;26:1039-1046.
45. Tanne D, Bates VE, Verro P, Kasner SE, Binder JR, Patel SC, Mansbach HH, Daley S, Schultz LR, Karanjia PN, Scott P, Dayno JM, Vereczkey-Porter K, Benesch C, Book D, Coplin WM, Dulli D, Levine SR;t-PA Stroke Survey Group: Initial clinical experience with IV tissue plasminogen activator for acute ischemic stroke: a multicenter survey. Neurology 1999;53:424-427.
46. Lopez-Yunez AM, Bruno A, Williams LS, Yilmaz E, Zurru C, Biller J: Protocol violations in community-based rTPA stroke treatment are associated with symptomatic intracerebral hemorrhage. Stroke 2001;32:12-16.